Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences holders approve 2 million more plan shares, warrant exercise

Neutral Impact 3 of 5 shareholder Written later

At its July 7, 2026 annual meeting, Cellectar Biosciences stockholders approved adding 2,000,000 shares to the 2021 Stock Incentive Plan and approved exercising warrants for up to 39,618,078 shares of common stock under Nasdaq rules. Stockholders also elected Andrew Gu and Douglas J. Swirsky to three-year terms and ratified Deloitte & Touche LLP as auditor for fiscal 2026, so the vote could increase the share count available to shareholders.

Key points

  • Plan amendment approved: 1,706,640 for, 439,422 against, 13,825 abstain
  • Warrant exercise for up to 39,618,078 shares approved: 1,881,936 for, 55,004 against, 222,946 abstain
  • Andrew Gu and Douglas J. Swirsky elected as Class III directors for three-year terms
  • Non-binding say-on-pay vote approved: 1,438,422 for, 712,362 against

The filing

CompanyCellectar Biosciences, Inc. (CLRB)
Form8-K, current report
Filed with the SECJul 10, 2026, 5:13 PM ET
Accession number0001104659-26-082719

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.